癌症診斷相關各種聯盟情形:契約動向、企業、財務及預測

本報告提供癌症診斷相關各種聯盟相關契約相關調查分析，近幾年的各種契約趨勢，契約額及大製藥公司的契約概要，各契約區分、開發階段、治療領域、技術類型的名錄等彙整資料。

摘要整理

第1章 簡介

第2章 癌症診斷相關的各種契約動向

• 簡介
• 過去數年的癌症診斷相關聯盟
• 最活躍的癌症診斷契約企業
• 癌症診斷相關聯盟:各類型契約
• 癌症診斷相關聯盟:各治療領域
• 公開的資本交易的條件
  • 付款總額
  • 預付款金
  • 階段性付款
  • 權利金比率

第3章 主要契約

• 簡介
• 主要契約:各交易金額

第4章 大型製藥公司的癌症診斷契約

• 簡介
• 大型製藥公司的癌症診斷聯盟契約的利用法
• 大型製藥公司的癌症診斷聯盟企業簡介

第5章 癌症診斷聯盟契約名錄

• 簡介
• 癌症診斷聯盟契約名錄

第6章 癌症診斷契約:各技術類型

第7章 聯盟資源中心

• 線上聯盟
• 聯盟趨勢
• 相關資料

附錄

• 附錄1:企業名順序(A∼Z)
• 附錄2:各臨床實驗階段
  • 藥物研發
  • 前臨床
  • 第一階段
  • 第二階段
  • 第三階段
  • 認證中
  • 已上市
  • 處方(製劑)設計
• 附錄3:各交易類型
  • 資產購買
  • 大型製藥企業的轉出授權
  • 共同開發
  • 共同研究開發(R&D)
  • 共同販賣
  • 共同促銷
  • 共同研究開發協定(CRADA)
  • 交叉許可
  • 開發
  • 流通
  • 股票購買
  • 評估
  • 津貼
  • 合資企業
  • 許可證
  • 訴訟
  • 製造
  • 行銷
  • 物質移動
  • 選擇
  • 推銷
  • 研究
  • 調停
  • 衍生公司
  • 再授權
  • 供給
  • 技術移交
  • 契約結束
  • 保證
• 附錄4:各治療領域
• 附錄5:交易種類定義

關於Wildwood Ventures

• Current Partnering
• Current Agreements
• Current Partnering 最新報告

圖表一覽

The Global Cancer Diagnostics Partnering 2012-2018 report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global Cancer Diagnostics Partnering 2012-2018 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer diagnostics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer diagnostics partnering contract documents

Top cancer diagnostics deals by value

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,200 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

• In-depth understanding of Cancer Diagnostics deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
• Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
• Identify most active Cancer Diagnostics dealmakers since 2012
• Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Cancer Diagnostics Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

• Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2012
• Analysis of Cancer Diagnostics deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Cancer Diagnostics deals
• Access to Cancer Diagnostics contract documents
• Leading Cancer Diagnostics deals by value since 2012
• Most active Cancer Diagnostics dealmakers since 2012

In Global Cancer Diagnostics Partnering 2012-2018: Deal trends, players, financials and forecasts, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• The Global Cancer Diagnostics Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,200 Cancer Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Cancer Diagnostics Partnering 2012-2018 report provides the reader with the following key benefits:

• In-depth understanding of Cancer Diagnostics deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
• Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
• Identify most active Cancer Diagnostics dealmakers since 2012
• Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Diagnostics dealmaking

• 2.1. Introduction
• 2.2. Cancer Diagnostics partnering over the years
• 2.3. Most active Cancer Diagnostics dealmakers
• 2.4. Cancer Diagnostics partnering by deal type
• 2.5. Cancer Diagnostics partnering by therapy area
• 2.6. Deal terms for Cancer Diagnostics partnering
• 2.6.1 Cancer Diagnostics partnering headline values
• 2.6.2 Cancer Diagnostics deal upfront payments7
• 2.6.3 Cancer Diagnostics deal milestone payments
• 2.6.4 Cancer Diagnostics royalty rates

Chapter 3 - Leading Cancer Diagnostics deals

• 3.1. Introduction
• 3.2. Top Cancer Diagnostics deals by value

Chapter 4 - Most active Cancer Diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active Cancer Diagnostics dealmakers
• 4.3. Most active Cancer Diagnostics partnering company profiles

Chapter 5 - Cancer Diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer Diagnostics contracts dealmaking directory

Chapter 6 - Cancer Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking

Appendices

• Appendix 1 - Cancer Diagnostics deals by company A-Z
• Appendix 2 - Cancer Diagnostics deals by stage of development
• Discovery
• Preclinical
• Phase I
• Phase II
• Phase III
• Regulatory
• Marketed
• Formulation
• Appendix 3 - Cancer Diagnostics deals by deal type
• Asset purchase
• Assignment
• Bigpharma outlicensing
• Co-development
• Collaborative R&D
• Co-market
• Co-promotion
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Litigation
• Manufacturing
• Marketing
• Material transfer
• Option
• Promotion
• Research
• Settlement
• Spin out
• Sub-license
• Supply
• Technology transfer
• Termination
• Warranty
• Appendix 4 - Cancer Diagnostics deals by therapy area
• Appendix 5 -Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
• Table of figures
• Figure 1: Cancer Diagnostics partnering since 2012
• Figure 2: Active Cancer Diagnostics dealmaking activity since 2012
• Figure 3: Cancer Diagnostics partnering by deal type since 2012
• Figure 4: Cancer Diagnostics partnering by disease type since 2012
• Figure 5: Cancer Diagnostics deals with a headline value
• Figure 6: Cancer Diagnostics deals with an upfront value
• Figure 7: Cancer Diagnostics deals with a milestone value
• Figure 8: Cancer Diagnostics deals with a royalty rate value
• Figure 9: Top Cancer Diagnostics deals by value since 2012
• Figure 10: Most active Cancer Diagnostics dealmakers since 2012
• Figure 11: Online partnering resources
• Figure 12: Forthcoming partnering events